Bazedoxifene
- Generic Name
- Bazedoxifene
- Brand Names
- Duavee, Duavive, Conbriza
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34N2O3
- CAS Number
- 198481-32-2
- Unique Ingredient Identifier
- Q16TT9C5BK
- Background
Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as the prevention of postmenopausal osteoporosis in women.
- Indication
用于预防和治疗妇女绝经后的骨质疏松症。
- Associated Conditions
- Postmenopausal Osteoporosis, Moderate Menopausal Vasomotor Symptoms, Severe Vasomotor Symptoms Associated With Menopause
- Associated Therapies
- -
Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Hanyang University
- Target Recruit Count
- 114
- Registration Number
- NCT02602704
- Locations
- 🇰🇷
Hanyang University, Seoul, Korea, Republic of
A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
- Conditions
- Breast Cancer Stage IVMetastatic Invasive Breast CancerUnresectable Locally Advanced Invasive Breast Cancer
- Interventions
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT02448771
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Instituto Palacios
- Target Recruit Count
- 110
- Registration Number
- NCT02090400
- Locations
- 🇪🇸
Gabinete Médico Velázquez, Madrid, Spain
🇪🇸Instituto Palacios, Madrid, Spain
🇪🇸Instituto de Ginecología EGR, Madrid, Spain
A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women
- Conditions
- Healthy
- Interventions
- Drug: bazedoxifeneDrug: bazedoxifene/conjugated estrogens
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2
- Registration Number
- NCT01634789
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3187
- Registration Number
- NCT01470326
Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10497
- Registration Number
- NCT01416194
Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.
- Conditions
- Postmenopausal Osteoporosis
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2007-12-20
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 375
- Registration Number
- NCT00238745
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.